BPGbio Inc

BOSTON, MA, USA I October 24, 2024 I BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced its participation in then 7th Annual Targeted Protein Degradation (TPD) and Induced Proximity Summit , in Boston. BPGbio executive Vivek K. Vishnudas , Ph.D., Chief Technology Officer and R&D Site Head, will present a session titled, “A Novel & Differentiated Approach to Targeted Protein Degradation – Leveraging the Ubiquitin Conjugating Enzyme (E2) Family” on the first day of the conference, October 28. The session will highlight latest developments in the company’s protein homeostasis program as BPGbio continues to advance potential first-in-class E2-based therapeutics in both neurology and oncology. Key points of the presentation include: “Our pioneering E2-based protein degradation is reshaping the TPD landscape, setting us apart from the more traditional E3 approaches,” said Dr. Vishnudas. “By harnessing the power of the ubiquitin conjugating enzyme (E2) family, we’re unlocking entirely new therapeutic modalities. We are excited to collaborate with the biopharma community as we push the boundaries of this revolutionary field and bring forward novel solutions to address unmet medical needs.” TPD has recently emerged as a game-changing approach to address proteins that have been difficult to target or protein target that yield limited clinical benefits through traditional small molecule inhibition. While most conventional TPD strategies rely on the use of E3 ligases, new research has shown that E2 proteins—once considered elusive—can be harnessed for effective and precise protein degradation, opening new avenues for therapeutic intervention. BPGbio’s TPD program is at the forefront of this breakthrough, utilizing E2s to drive the development of innovative bifunctional degraders and monovalent molecular glues, opening new frontiers in drug discovery. In addition to utilizing E2s, the BPGbio’s protein homeostasis program features a proprietary library of more than 1,000 Ro3 fragments discovered by BPGbio that are potential ligands and seed compounds to a variety of E2 targets, proprietary ternary structures, a computational tool kit for E2 ligand design, and assays for rapidly attaining selectivity and specificity. About BPGbio BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi , its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com . SOURCE: BPGbio

BOSTON, MA, USA & OXFORD, UK I October 07, 2024 I BPGbio, Inc. , a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis , and the University of Oxford’s Centre for Medicines Discovery , today announced a five-year research collaboration focused on advancing novel protein degradation technologies, particularly in oncology and central nervous system (CNS) diseases, with the goal of unlocking new therapeutic pathways for conditions with limited treatment options. The organizations will work in phases, starting with the validation of BPGbio’s novel E2 TPD technology, and expanding into future study of the degradable target space, to identify novel targets and generate high quality publications. This collaboration builds on BPGbio’s first-in-class E2-based protein degradation program, which features a proprietary library of more than 1,000 Ro3 fragments discovered by BPGbio that are potential ligands and seed compounds to a variety of E2 targets. The collaboration will also utilize BPGbio’s proprietary ternary structures, its computational toolkit for E2 ligand design, and assays for rapidly attaining selectivity and specificity. The partnership will leverage the Centre for Medicines Discovery’s expertise in translational research, including their groundbreaking efforts in neurological diseases such as Parkinson’s Disease. The team will utilize BPGbio’s proprietary NAi Interrogative Biology® Platform , which integrates patient biology with AI-driven analysis, to accelerate biomarker discovery and therapeutics development. “This collaboration represents a powerful alliance of biology-first science and cutting-edge translational research,” said Niven R. Narain, Ph.D. , President and CEO of BPGbio. “By harnessing our NAi Interrogative Biology Platform alongside the University of Oxford’s expertise, we aim to push the boundaries of protein degradation science and deliver transformative therapies for diseases like cancer and CNS disorders, where unmet medical needs remain significant.” “By partnering with BPGbio, we’re combining our world-class translational research expertise with their pioneering approach to protein degradation,” said Prof. Paul Brennan, Ph.D., FRSC , Director of the Centre for Medicines Discovery at University of Oxford. “This collaboration has the potential to unlock new therapeutic strategies for diseases that have long resisted treatment, including challenging cancers and CNS disorders. We are excited to explore novel targets and bring forward breakthrough therapies that could make a profound difference for patients.” To learn more about BPGbio’s protein homeostasis program and quest to address targets believed to be undruggable, visit https://bpgbio.com/protein-homeostasis/ . About BPGbio BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi , its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com . About The Centre for Medicines Discovery at the University of Oxford The Centre for Medicines Discovery is a multi-disciplinary Institute within the University of Oxford’s Nuffield Department of Medicine which focuses upon translational activities to catalyse the discovery and development of new medicines for patients. We focus upon inherited and rare diseases, anti-microbial resistance, autoimmunity, inflammation, GI, respiratory, cardiometabolic & CNS diseases with a view to generating new tools, technologies and methodologies to transform drug targeting and pre-clinical development. We build upon cutting-edge technologies such as genetics & genomics, molecular, structural & single cell biology as well as spatial imaging to transform drug targeting and pre-clinical development. SOURCE: BPGbio

Vevizye’s effectiveness in treating DED was confirmed by two placebo-controlled trials. Credit: fizkes via Shutterstock. Novaliq and Laboratoires Théa have announced approval from the European Commission (EC) for Vevizye (ciclosporin 0.1% eye drops solution) for patients with dry eye disease (DED) in Europe. The partnership between the two companies has also been closed, with Théa acquiring the rights to commercialise Vevizye in Europe and selected Middle East and North African countries. Vevizye is the only water-free ciclosporin 0.1% eye drop solution that received approval in the EU to treat moderate to severe DED in adults who have not responded to tear substitute treatments. Novaliq CEO Christian Roesky said: “Théa’s focus on innovation, its leading commercial capabilities and the strong track record in Europe makes them the perfect partner for Novaliq.” DED affects an estimated 15 million diagnosed patients in the five largest European countries and presents a significant treatment challenge. See Also: Potential for peptides to replace antibodies in radiopharma, says WuXi AppTec exec BPGbio’s mitochondrial disorder drug gets paediatric disease status The efficacy of the product for treating DED was established through two randomised, double-masked, multicentre, vehicle-controlled studies, ESSENCE-1 and ESSENCE-2. The primary endpoint in both trials was the change from baseline in total corneal fluorescein staining (tCFS) score at Day 29. Results showed a statistically significant reduction in tCFS, with up to 71.6% of patients experiencing clinical improvement within four weeks. Statistically significant effects were also observed in all other key secondary ocular surface sign endpoints. In the US, the Food and Drug Administration approved the product as VEVYE in May 2023. Vevizye received approval in all 27 EU member states. In August 2023, the European Medicines Agency accepted Novaliq’s marketing authorisation application f or CyclASol, another cyclosporine ophthalmic solution at 0.1%, as a treatment for DED.